ML13303A450

Submittal of the Phase I Archaeological Survey of the Proposed Shine Medical Isotope Production Facility

ML13303A450
Person / Time
Site:	SHINE Medical Technologies
Issue date:	10/28/2013
From:	Bynum R SHINE Medical Technologies
To:	Document Control Desk, Office of Nuclear Reactor Regulation
Shared Package
ML13303A442	List: ML13303A450
References
SMT-2013-038
Download: ML13303A450 (5)

Text

J SHINE Medical Technologies THIS LETTER CONTAINS PROPRIETARY INFORMATION IN ACCORDANCE WITH 10 CFR 2.390 October 28, 2013 SMT-2013-038 10 CFR 50.30 U.S. Nuclear Regulatory Commission ATTN: Document Control Desk Washington, DC 20555

References:

(1) SHINE Medical Technologies, Inc. letter to NRC, dated March 26, 2013, Part One of the SHINE Medical Technologies, Inc. Application for Construction Permit (ML130880226)

(2) SHINE Medical Technologies, Inc. letter to NRC, dated May 31, 2013, Part Two of the SHINE Medical Technologies, Inc. Application for Construction Permit (ML13172A361)

Submittal of the Phase I Archaeological Survey of the Proposed SHINE Medical Isotope Production Facility Pursuant to 10 CFR 50.30, SHINE Medical Technologies, Inc. (SHINE) submitted an application for a construction permit to construct a medical isotope facility to be located in Janesville, WI (References 1 and 2). During a teleconference on October 23, 2013, NRC staff requested SHINE provide the Phase I archaeological survey of the project area for the proposed SHINE medical isotope production facility. provides the Phase I archaeological survey of the proposed SHINE medical isotope production facility. Enclosure 1 contains information specifically exempted from disclosure by statute, in accordance with Section 304 of the National Historic Preservation Act. SHINE requests that the NRC withhold Enclosure 1 in its entirety from public disclosure under 10 CFR 2.390.

Enclosure 2 provides an affidavit supporting the proprietary treatment of Enclosure 1, pursuant to 10 CFR 2.390.

If you have any questions, please contact Mr. Jim Costedio, Licensing Manager, at 608/210-1730.

Enclosure 1 contains proprietary information.

Withhold from public disclosure under 10 CFR 2.390.

Upon removal of Enclosure 1, this letter is uncontrolled.

2555 Industrial Drive I Monona, WI 53713 1P (608) 210-10601 F (608) 210-2504 1www.shinemed.com

Document Control Desk Page 2 THIS LETTER CONTAINS PROPRIETARY INFORMATION IN ACCORDANCE WITH 10 CFR 2.390 I declare under the penalty of perjury that the foregoing is true and correct.

Executed on October 28, 2013.

Very truly yours, R. Vann Bynum, Ph.D.

Chief Operating Officer SHINE Medical Technologies, Inc.

Docket No. 50-608 Enclosures cc: Administrator, Region III, USNRC Project Manager, USNRC Environmental Project Manager, USNRC Supervisor, Radioactive Materials Program, Wisconsin Division of Public Health Enclosure 1 contains proprietary information.

Withhold from public disclosure under 10 CFR 2.390.

Upon removal of Enclosure 1, this letter is uncontrolled.

ENCLOSURE 2 SHINE MEDICAL TECHNOLOGIES, INC.

SUBMITTAL OF THE PHASE I ARCHAEOLOGICAL SURVEY OF THE PROPOSED SHINE MEDICAL ISOTOPE PRODUCTION FACILITY AFFIDAVIT OF RICHARD VANN BYNUM 2 pages follow

• SHINETP Medical Technologies AFFIDAVIT OF RICHARD VANN BYNUM STATE OF WISCONSIN

)ss.

COUNTY OF DANE I, Richard Vann Bynum, Chief Operating Officer of SHINE Medical Technologies, Inc. (SHINE),

do hereby affirm and state:

1. I am authorized to execute this affidavit on behalf of SHINE. I am authorized to review information submitted to or discussed with the Nuclear Regulatory Commission (NRC) and apply for the withholding of information from public disclosure. The purpose of this affidavit is to provide the information required by 10 CFR 2.390(b) in support of SHINE's request for proprietary treatment of confidential commercial information submitted in the Phase I Archaeological Survey of the Proposed SHINE Medical Isotope Production Facility. SHINE requests that the confidential information contained in Enclosure 1 be withheld from public disclosure in its entirety.

2. I have knowledge of the criteria used by SHINE in designating information as sensitive, proprietary, or confidential.

3. Pursuant to the provisions of paragraph (a)(3) of 10 CFR 2.390, the following is furnished for consideration by the NRC in determining whether the information sought to be withheld from public disclosure should be withheld.

a. The information sought to be withheld from public disclosure contained in Enclosure 1 of SMT-2013-038 is owned by SHINE, its affiliates or third parties to whom SHINE has an obligation to maintain its confidentiality. This information is and has been held in confidence by SHINE.

b. The information sought to be protected in Enclosure 1 is not available to the public to the best of my knowledge and belief.

c. The information contained in Enclosure 1 contains information about the location, character, or ownership of historic resources protected by Section 304 of the National Historic Preservation Act.

1

d. The proprietary information sought to be withheld from public disclosure in Enclosure 1 is the document, "A Phase I Archaeological Survey of the Proposed SHINE Medical Isotope Production Facility, Near Janesville, Rock County, Wisconsin."

e. The information contained in Enclosure 1 of letter SMT-2013-038 is transmitted to the NRC in confidence and under the provisions of 10 CFR 2.390; it is to be received in confidence by the NRC. The information is properly marked.

I declare under the penalty of perjury that the foregoing is true and correct.

Executed on October 28, 2013.

Richard Vann bynum, Ph.D.

COO - SHINE Medical Technologies, Inc.

2